← Back to Search

NMDA Receptor Antagonist

Ketamine for Suicidal Thoughts

Phase 1

Recruiting

Research Sponsored by Lindsay Maguire, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 72 hours

Awards & highlights

Study Summary

This trial will test if ketamine can be used to reduce suicidal thoughts in those who present to an Emergency Dept.

Who is the study for?

This trial is for individuals in the emergency department with suicidal thoughts or behaviors, who are fully conscious (GCS 15). It's not suitable for those with a history of psychosis, clinical intoxication, extreme blood pressure issues, pregnancy, inability to consent, known adverse reactions to ketamine, involuntary psychiatric hold or those needing medical admission.Check my eligibility

What is being tested?

The study tests low-dose intravenous ketamine as an immediate treatment for patients presenting with suicidal ideation in the emergency department. The goal is to see if it's feasible and safe to use this drug that has shown promise in treating resistant depression.See study design

What are the potential side effects?

Ketamine can cause side effects such as disorientation, changes in blood pressure and heart rate, dizziness, nausea or vomiting. Some people might experience mood swings or feel detached from reality temporarily.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 72 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~72 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]

Secondary outcome measures

Change in Suicidal Ideation

Hospital Length of Stay

Trial Design

1Treatment groups

Experimental Treatment

Group I: KetamineExperimental Treatment1 Intervention

All patients will receive the experimental drug.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

2011

Completed Phase 4

~1090

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Lindsay Maguire, MDLead Sponsor

University of Kansas Medical CenterLead Sponsor

465 Previous Clinical Trials

169,249 Total Patients Enrolled

5 Trials studying Depression

385 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the use of Ketamine associated with any health hazards?

"Due to limited data on safety and efficacy, the perceived risk of ketamine was rated as 1."

Answered by AI

Does the eligibility for this experiment extend to those under sixty years of age?

"The eligibility for this medical study requires that participants are within the age range of 18 to 65. Separately, there is a set of 302 clinical trials available for individuals younger than 18 and 1172 research studies designed for those older than 65."

Answered by AI

Do I meet the criterion to partake in this experiment?

"To qualify for this medical trial, participants must have attempted suicide and be between the ages of 18-65. The total required number of patients is 50."

Answered by AI

Is there still an opportunity for individuals to join this research experiment?

"The clinical trial mentioned is no longer recruiting new participants, as the latest update on its posting was made 10/10/2023. Nonetheless, there are a substantial number of other trials that remain open to applicants at this time; 1620 in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

Lindsay Maguire, MD 2024. "Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06085937.

All > Depression Kansas City > Kansas City